0001622667-22-000003.txt : 20220811 0001622667-22-000003.hdr.sgml : 20220811 20220811110148 ACCESSION NUMBER: 0001622667-22-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 EFFECTIVENESS DATE: 20220811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEON Biopharma, Inc. CENTRAL INDEX KEY: 0001622667 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454777018 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-455629 FILM NUMBER: 221154328 BUSINESS ADDRESS: STREET 1: 5 PARK PLAZA STREET 2: SUITE 1750 CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 949-298-2211 MAIL ADDRESS: STREET 1: 5 PARK PLAZA STREET 2: SUITE 1750 CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: Alphaeon Corp DATE OF NAME CHANGE: 20141017 D 1 primary_doc.xml X0708 D LIVE 0001622667 AEON Biopharma, Inc. 5 PARK PLAZA SUITE 1750 IRVINE CA CALIFORNIA 92614 949-298-2211 CALIFORNIA Alphaeon Corp Corporation true Simone Blank 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Director Jost Fischer 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Director Robert Grant 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Director Vikram Malik 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Director Darren O'Brien 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Director Richard Taketa 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Director Marc Forth 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Executive Officer Chris Carr 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Executive Officer Alex Wilson 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Executive Officer Chad Oh 5 Park Plaza, Suite 1750 Irvine CA CALIFORNIA 92614 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2021-12-08 false true true true true The convertible promissory notes may be paid in cash or converted into an indeterminate number of shares of Common Stock. false 0 25000000 24500000 500000 Pursuant to a Subord. Unsecured Convert. Prom. Note Purchase Agreement dated 12.8.21, as amended, the Company agreed to sell and issue, and a single accredited investor agreed to purchase, notes in an aggregate principal amount not to exceed $25,000,000. false 1 0 0 0 false AEON Biopharma, Inc. /s/ Alex Wilson Alex Wilson Gen. Counsel and Secty. 2022-08-10